SCIENTIFIC REPORTS

OPEN

Author Correction: Serum GFAP as a biomarker for disease severity in multiple sclerosis

A. Abdelhak[1], A. Huss[2], J. Kassubek[1], H. Tumani[1,3] & M. Otto[1]

Published online: 05 June 2019

Correction to: *Scientific Reports* https://doi.org/10.1038/s41598-018-33158-8, published online 04 October 2018

In Figure 5, the values for the PMS subgroup are duplicated in both 5a and 5b. The correct Figure 5 appears below as Figure 1.



Figure 1. Quotient of glial fibrillary acidic protein (GFAP) and neurofilaments light (NfL) in cerebrospinal fluid (CSF) and serum in progressive multiple sclerosis patients (PMS) compared to relapsing-remitting multiple sclerosis (RRMS). n.s.: not significant.

[1]Department of Neurology, University Hospital of Ulm, Ulm, Germany. [2]Department of Experimental Neurology, University of Ulm, Ulm, Germany. [3]Speciality Clinic of Neurology Dietenbronn, Schwendi, Germany. A. Abdelhak and A. Huss contributed equally. H. Tumani and M. Otto jointly supervised this work. Correspondence and requests for materials should be addressed to M.O. (email: markus.otto@uni-ulm.de)

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019